← Leaderboards
Paula J Bates
University Of Louisville
$4,472,619
Attributed
$7,775,739
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1000K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,775,739 · 5
By mechanism
U01$5,940,111 · 2
R01$1,283,028 · 1
R21$552,600 · 2
Top collaborators
- Linda P Dwoskin3 shared
- Donald M Miller3 shared
- Eugene Krentsel2 shared
Most similar at University Of Louisville
Same institution · by research overlap
- Martha E Bickford$21,342,181
- Eugene Krentsel$2,311,090
- Donald M Miller$9,881,293
- John O Trent$4,178,948
- Randall Davis$366,099
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureProgramsMemberMentorsInterestMalignant NeoplasmsDevicesBaseGrantFederal GovernmentInnovationInstitutionKentuckyLeadershipBackClinical TrialsCommercializationDesignBusinessesFundingBiomedical ResearchEntrepreneurshipIndustryEconomic Development
Grant awards (15)
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$967,861
U01 · FY2021 · HL
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$977,377
U01 · FY2020 · HL
Kentucky Network for Innovation & Commercialization (âKYNETICâ)$999,998
U01 · FY2019 · HL
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$996,487
U01 · FY2017 · HL · contact PI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$999,194
U01 · FY2016 · HL · contact PI
The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship$999,194
U01 · FY2015 · HL · contact PI
Tumor-Targeting Oligonucleotides$255,082
R01 · FY2010 · CA · contact PI
Tumor-Targeting Oligonucleotides$255,082
R01 · FY2009 · CA · contact PI
Tumor-Targeting Oligonucleotides$255,082
R01 · FY2008 · CA · contact PI
Tumor-Targeting Oligonucleotides$255,082
R01 · FY2007 · CA · contact PI
Tumor-Targeting Oligonucleotides$262,700
R01 · FY2006 · CA · contact PI
A Role for Nucleolin in Malignant Transformation?$132,300
R21 · FY2005 · CA
A Role for Nucleolin in Malignant Transformation?$132,300
R21 · FY2004 · CA
Nucleolin--A Novel Target for Cancer Drug Discovery$144,000
R21 · FY2002 · CA
Nucleolin--A Novel Target for Cancer Drug Discovery$144,000
R21 · FY2001 · CA